PF 07265028
Alternative Names: PF-07265028Latest Information Update: 27 Mar 2024
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Head and neck cancer; Solid tumours
Most Recent Events
- 25 Mar 2024 Pfizer terminates phase I clinical trial in Head and neck cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan and USA, due to internal business considerations and was not based on safety reasons (PO) (NCT05233436)
- 25 Mar 2024 Pfizer terminates phase I clinical trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Japan (PO) (NCT05233436)
- 25 Mar 2024 Pfizer terminates phase I clinical trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Japan and USA due to internal business considerations and was not based on safety reasons (PO) (NCT05233436)